LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $94.57.

A number of brokerages have recently issued reports on LMAT. Barrington Research upped their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday. Oppenheimer reissued an “outperform” rating and issued a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a report on Friday. JMP Securities increased their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Finally, StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total transaction of $251,380.41. Following the transaction, the director now owns 14,114 shares in the company, valued at $1,158,335.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 10.79% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Several large investors have recently made changes to their positions in LMAT. Driehaus Capital Management LLC boosted its position in shares of LeMaitre Vascular by 52.2% during the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock worth $21,740,000 after acquiring an additional 90,573 shares in the last quarter. F M Investments LLC acquired a new stake in shares of LeMaitre Vascular during the 2nd quarter worth approximately $7,443,000. Nicholas Investment Partners LP acquired a new stake in LeMaitre Vascular in the second quarter valued at approximately $3,900,000. Janus Henderson Group PLC boosted its position in LeMaitre Vascular by 554.7% in the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock valued at $3,697,000 after buying an additional 47,218 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in LeMaitre Vascular by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after buying an additional 38,303 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $94.88 on Friday. The firm’s 50-day moving average is $89.59 and its 200-day moving average is $83.11. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of 51.85, a PEG ratio of 2.32 and a beta of 0.89. LeMaitre Vascular has a 52-week low of $45.96 and a 52-week high of $101.67.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.39%. LeMaitre Vascular’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.33 EPS. Sell-side analysts predict that LeMaitre Vascular will post 1.86 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a dividend of $0.16 per share. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.67%. LeMaitre Vascular’s payout ratio is presently 34.97%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.